

BIOGEN IDEC - Investing for Long-Term

<https://marketpublishers.com/r/B6948DFA01FEN.html>

Date: February 2012

Pages: 9

Price: US\$ 140.00 (Single User License)

ID: B6948DFA01FEN

Abstracts

Biogen Idec (BIIB) promises to enrich its revenue stream and MS franchise in 2012 with the launch of oral BG-12 (Dimethyl fumarate, R). Clinical news flow from rFactorVIII (PhIII, hemophilia A) and rFactorIX (PhIII, hemophilia B) will make its presence felt in the Hemophilia market while success of Dexpramipexole (PhIII) in Amyotrophic Lateral Sclerosis (ALS) could fill in a significant unmet need! With the updated Tysabri's (L, natalizumab, RRMS; PhIII in SPMS) label including screening for JCV, approval of Avonex PEN, and additional launches of FAMPRYA (L, RRMS); BIIB expects growth in single-digit for 2012. For more detail, please read our report released on 8th Feb., 2012 on Biogen Idec titled "Investing for Long-Term".

Contents

COMPANIES MENTIONED

BIOGEN IDEC

I would like to order

Product name: BIOGEN IDEC - Investing for Long-Term

Product link: <https://marketpublishers.com/r/B6948DFA01FEN.html>

Price: US\$ 140.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B6948DFA01FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970